Abbvie

This phase 3 trial tests the drug lutikizumab against a placebo in about 1400 adults and teens with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants receive weekly shots for 16 weeks, then continue on differen…

This study follows about 772 teenagers and adults with moderate to severe eczema who are taking upadacitinib (Rinvoq) as prescribed by their doctor. Researchers want to see how well the drug controls the disease over two years in everyday medical practice. Participants will have …

This study tests whether the drug ubrogepant can prevent menstrual migraines when taken daily for a week around each period. About 496 women with regular cycles and a history of menstrual migraines will receive either ubrogepant or a placebo for three cycles, then all may receive…

This study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils in the armpits, groin, and genital area. The trial includes about 1,328 adults and teens who have not improved with standard …

This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…

This early-stage study tests a new drug called etentamig combined with standard treatments for people with multiple myeloma that has come back or stopped responding to therapy. About 320 adults will take part to find the safest dose and check for side effects. The goal is to cont…

This clinical trial is testing whether risankizumab, an experimental drug, can safely and effectively maintain remission in people with moderate to severe Crohn's disease who have already responded to initial treatment. Participants will receive either risankizumab or a placebo f…

This study tests a drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema) that hasn't improved with standard treatments. About 80 participants will receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 32 weeks. …

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This study is a long-term follow-up for people who previously received an injection of RGX-314, a gene therapy, for diabetic retinopathy (with or without diabetic macular edema). The purpose is to monitor the safety and effectiveness of the treatment over a total of five years af…

This study follows people who previously received an experimental gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see how safe and effective the treatment remains over up to five years after the injection.…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study compares two approved drugs, risankizumab and vedolizumab, in about 530 adults with moderate to severe ulcerative colitis who have not tried targeted therapies before. Participants will receive one of the two drugs for about a year. The main goal is to see which drug b…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…

This study is testing an oral medication called upadacitinib in children with polyarticular juvenile idiopathic arthritis (JIA), a condition causing joint inflammation. The goal is to understand how the drug moves through the body, its safety, and how well children tolerate it. P…

This study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how ma…

This study tests a daily pill called upadacitinib for people with severe alopecia areata, an immune system attack on hair follicles causing at least 25% scalp hair loss. About 123 teens and adults in Japan will take either the drug or a placebo for up to 104 weeks to see if it sa…

This Phase 2 study tests a new drug, telisotuzumab adizutecan (ABBV-400), combined with standard chemotherapy and an immunotherapy drug for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will recei…

This study follows 400 adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib (RINVOQ) by their doctor. Researchers will track how well the drug controls symptoms like diarrhea and rectal bleeding over two years. The goal is to see if early impr…

This early-stage study tests a new drug called ABBV-969 in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the best dose. About 230 participants worldwide will receive the drug…

This phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitid…

This Phase 3 trial tests upadacitinib (Rinvoq), an oral immune-calming drug, in about 540 adults and teens with non-segmental vitiligo. Participants take a pill once daily for up to 160 weeks, with some receiving placebo first. The study measures how much skin color returns and t…

This study looks at how well the migraine prevention drug atogepant works in real-world settings. Over 1000 adults with migraine who are already prescribed atogepant will be followed for 2 years. Researchers will measure how much patients feel their migraines have improved since …

This Phase 3 trial is testing whether adding mirvetuximab soravtansine (a drug that targets a protein called FRα on cancer cells) to standard bevacizumab maintenance therapy can delay cancer progression in women with recurrent ovarian, fallopian tube, or peritoneal cancer. The st…

This phase 3 trial tests two different doses of an investigational drug called telisotuzumab adizutecan in about 74 adults with metastatic colorectal cancer that has stopped responding to standard treatments and whose tumors have a specific protein (c-Met). The drug is given by I…

This study looks at how well upadacitinib (RINVOQ) works for people with axial spondyloarthritis, a type of inflammatory arthritis that causes chronic back pain. About 338 adults in Germany will take the drug as prescribed by their doctor and be followed for 52 weeks. Researchers…

This program gives eligible people with acute spinal cord injury early access to the investigational drug elezanumab before it is officially approved. A doctor must decide if the potential benefit outweighs the risks for each patient. The program is only available in certain terr…

This study tests an implant called AGN-193408 SR that is placed inside the eye to lower pressure in people with open-angle glaucoma or ocular hypertension. About 100 participants will receive the implant, and some will also get standard eye drops for comparison. The goal is to se…

This program provides early access to telisotuzumab vedotin, an investigational drug, for eligible people with non-small cell lung cancer who have no other treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous infus…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This study follows 250 adults with advanced Parkinson's disease who are prescribed ABBV-951 by their doctors. The goal is to see how safe and effective the drug is in everyday use over 52 weeks. Participants continue their normal care with no extra visits required.

This study tests an oral medication called upadacitinib in children aged 2 to 17 with moderate-to-severe ulcerative colitis who have not improved with standard treatments. The goal is to see if the drug can reduce inflammation and control symptoms like diarrhea and bleeding. Part…

This early-phase study tests an investigational drug called telisotuzumab adizutecan in about 30 Chinese adults with advanced colorectal cancer that cannot be removed by surgery. The main goals are to check safety and how the drug moves through the body. Participants receive diff…

This early-phase trial tests an investigational drug called ABBV-706, alone or combined with other drugs, in about 288 adults with advanced solid tumors like small cell lung cancer, high-grade brain tumors, and neuroendocrine cancers. The main goals are to check safety, find the …

This study tests whether adding the drug venetoclax to standard azacitidine treatment helps people with a severe form of myelodysplastic syndrome (MDS) live longer. MDS is a bone marrow disorder that can lead to leukemia. About 500 adults with newly diagnosed high-risk MDS will r…

This early-stage trial tests an experimental oral drug called ABBV-525 in people with B-cell blood cancers like lymphoma and leukemia. The study aims to find a safe dose and check for side effects. About 78 adults will take the drug in different dose groups over up to 64 months.

This study tests a small device called XEN45 that is implanted in the eye to help drain fluid and lower pressure in people with open-angle glaucoma. About 120 adults in China will receive either the XEN45 implant or standard glaucoma surgery. Researchers will track eye pressure a…

This study follows about 427 adults with advanced Parkinson's disease who are receiving ABBV-951, a continuous infusion under the skin. Researchers want to see how well it controls symptoms like tremors and stiffness over three years in everyday medical practice. Participants att…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to help the eye produce its own medicine to stop leaky blood vessels, potentially replacing the need for repeated eye injecti…

This phase 3 study tests whether upadacitinib (RINVOQ), a drug already used for arthritis, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. Researchers will measure how well it reduces disease acti…

This study tests whether risankizumab works better than ustekinumab for adults with moderate to severe Crohn's disease who have not responded to anti-TNF therapy. About 527 participants will receive either drug through IV and then injections over nearly a year, with some continui…

This phase 3 trial tests whether upadacitinib (RINVOQ), a daily oral medication, can help adults with Crohn's disease maintain remission after initial treatment. About 747 participants who responded to upadacitinib in earlier studies will receive either the drug or a placebo. The…

This early-phase study tests an experimental drug called etentamig (ABBV-383) in about 55 adults with multiple myeloma that has returned or not responded to prior treatments. The drug is given as a shot under the skin or through an IV. The main goals are to check safety, side eff…

This study tests a gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment is given as one or two injections into the eye and aims to produce proteins that block abnormal blood vessel growth, potentially replacing …

This study looks at how well a drug called foslevodopa-foscarbidopa works for people with advanced Parkinson's disease in France. About 250 adults whose doctors have already prescribed this drug will be followed for up to 12 months. The goal is to see if the treatment improves th…

This study tests whether upadacitinib (Rinvoq), a daily pill already used in older patients, can safely improve moderate to severe eczema in children aged 2 to 11 in Japan. About 99 kids will receive either the drug or a placebo, plus a steroid cream, for up to a year. Researcher…

This early-stage trial is testing a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers, including ovarian, endometrial, and cervical cancers. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to cells that have a s…

This phase 3 trial tests whether upadacitinib (Rinvoq) can help people with Takayasu arteritis, a rare disease that inflames large arteries. About 56 adults who have had a recent relapse despite steroids will receive either upadacitinib or a placebo, along with a steroid taper. T…

This phase 2 trial tests an investigational drug called lutikizumab (ABT-981) in about 210 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing lumps and abscesses. The main study includes people who have already tried and failed anti-TNF…

This program offers early access to the investigational drug ABBV-787 for people with acute myeloid leukemia (AML) who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefit outweighs the risks. The drug is …

This study tests a new drug called TNB-383B in about 220 adults with multiple myeloma that has come back or not responded to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The main goals are to find the safest dose and check for …

This study follows 250 adults in Greece who were recently diagnosed with moderate plaque psoriasis and are starting risankizumab, a drug that calms the overactive immune system. Researchers will measure how much the skin clears up and how quality of life improves over two years. …

This phase 3 study tests whether risankizumab, an injected drug, can safely maintain remission in people with ulcerative colitis who already improved with the same drug. Over 1,200 participants will receive either risankizumab or a placebo for 52 weeks, with an option to continue…

This study follows about 100 adults with acute myeloid leukemia (AML) who are already prescribed venetoclax by their doctors in Israel. Researchers will track how long patients live and how many achieve remission during routine care. The goal is to understand the drug's real-worl…

This program offers early access to fosigotifator, an oral drug, for people with Vanishing White Matter or Cree Leukoencephalopathy—two rare, serious brain diseases. A doctor must decide if the potential benefit outweighs the risks for each patient. The drug is not yet approved, …

This study tests the long-term safety and effectiveness of upadacitinib (RINVOQ) in about 950 people with ulcerative colitis who didn't respond well to earlier treatment. Participants take the drug or a placebo orally. The goal is to see if it can control the disease over time wi…

This study tests whether adding the experimental drug navitoclax to the standard drug ruxolitinib can shrink the spleen and reduce symptoms better than other available treatments in adults with myelofibrosis that has returned or not improved. About 330 participants will be random…

This early-phase study tests an experimental drug called ABBV-453, given with another cancer drug (obinutuzumab), in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. About 60 participa…

This early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to other treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 parti…

This study tests whether a daily pill called upadacitinib, used with a steroid cream, can safely reduce eczema symptoms like itching and redness in teens and adults with moderate-to-severe disease. About 1,500 participants took the pill or a placebo for 16 weeks. The main goals w…

This study tests a new drug, ABBV-400, combined with standard treatments for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 280 adults who have already tried one prior treatment will receive different doses of ABBV-400 plus chemothe…

This study looks at how well the drug venetoclax works for adults with acute myeloid leukemia (AML) who cannot handle strong chemotherapy. About 210 people across Canada will take venetoclax pills daily as part of their normal care. Researchers will track their overall survival a…

This study tests an experimental drug, telisotuzumab vedotin, in adults with a certain type of advanced lung cancer (c-Met+ non-small cell lung cancer) that has already been treated. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that have …

This study tests a two-step treatment for a type of ovarian cancer that has come back after initial chemotherapy. First, patients receive a standard chemo drug (carboplatin) plus a targeted drug (mirvetuximab) that homes in on a protein called FRα found on cancer cells. Then, the…

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This study tests a new drug called lutikizumab in about 156 adults with moderate to severe ulcerative colitis, a condition causing inflammation and bleeding in the colon. Participants receive either lutikizumab or adalimumab (Humira) for 12 weeks, then continue based on response.…

This phase 2 trial tests RGX-314, a gene therapy given as a single injection into the eye, for people with diabetic retinopathy. The goal is to see if it can improve vision and reduce the need for frequent anti-VEGF injections. About 139 adults with diabetes-related eye damage ar…

This phase 3 trial is testing whether risankizumab (Skyrizi) can help people with moderate-to-severe Crohn's disease. About 289 adults will receive either the drug or a placebo as a shot under the skin for up to 24 weeks, followed by an open-label extension. The goal is to see if…

This study tests a new medicine called atogepant to prevent migraines that happen around a woman's period. About 430 adult women with regular cycles and a history of migraines will take either atogepant or a placebo daily for 3 menstrual cycles. The goal is to see if the drug red…

This early-stage study is testing a new drug called ABBV-295 in 24 healthy Japanese adults who are overweight or obese. The main goal is to check the drug's safety and how the body processes it. Participants receive injections of the drug or a placebo, and researchers monitor for…

This study tests whether atogepant, a drug already used to prevent migraines, can also treat migraine attacks quickly. About 1300 adults with a history of migraines will take either atogepant or a placebo when they have a migraine, and then report pain levels and symptoms after 2…

This study tests a new artificial tear called ABBV-444 against an existing brand, Refresh Optive, in 250 adults with dry eye disease. Participants use the assigned eye drops for 90 days. The goal is to see if the new formula improves eye comfort and surface health better than the…

This study tests whether adding the drug elagolix to birth control pills can reduce moderate to severe pain from endometriosis. About 800 premenopausal women with surgically confirmed endometriosis will take either elagolix plus birth control or a placebo for 3 months, then all w…

This study tests an injectable gel called ELAPR002f for adults with indented acne scars on the cheeks. About 157 participants will receive either the gel or a saline placebo over 2 months and be followed for a year. The goal is to see if the gel safely fills in scars and improves…

This early-stage study tests a single dose of ABBV-547 in healthy adults to check its safety, how the body processes it, and any side effects. About 121 participants in the US and Japan will receive either the drug or a placebo. The study has two parts with different dosing group…

This early-stage study is testing whether a new drug called ABBV-722 changes how the body processes several common medications. Twelve healthy adults will take ABBV-722 along with a 'cocktail' of other drugs (midazolam, digoxin, pitavastatin, metformin, and sitagliptin) to see if…

This Phase 1 study will give a single dose of ABBV-932 (with a tiny radioactive marker) to 8 healthy men. The goal is to measure how the drug moves through the body, how long it stays, and how it is eliminated. Researchers will also check for any side effects. This is a safety an…

This observational study follows about 236 adults with diabetic macular edema (DME) who did not respond well to anti-VEGF injections and are now starting treatment with a dexamethasone implant (DEX-I). The implant slowly releases steroid medication into the eye. Researchers will …

This study watches how people with chronic lymphocytic leukemia (CLL) feel and function while taking standard oral treatments. About 146 adults in Spain will fill out questionnaires about their symptoms, fatigue, and worries during routine doctor visits. No new drugs are given—th…

This early-stage study looks at how a new drug called ABBV-295 interacts with common birth control pills in healthy adult women who are overweight or obese. The goal is to check for side effects and measure drug levels in the body. About 20 women will take part, and the results w…

This early-stage study is testing a new drug called ABBV-701 in about 100 healthy adults from Western and Asian backgrounds. The goal is to check its safety, how the body processes it, and whether it triggers an immune response. Participants receive a single dose and are monitore…

This study follows 110 adults with diabetic macular edema who are prescribed OZURDEX (a dexamethasone implant placed in the eye) by their doctors in routine Chinese clinics. Researchers will track side effects like cataracts, high eye pressure, and bleeding over two years. The go…

This study was designed to track hair loss in women with uterine fibroids who are taking the medication Oriahnn. Researchers planned to follow about 1,600 women for up to 24 months, using questionnaires and scalp photos to see how common hair loss is, when it starts, and if it go…